Peptide Genomics: Why One Size Doesn't Fit
Your genome shapes how you metabolize peptides and drugs — which ones work for you, which ones cause side effects, and which doses you actually need. The case for personalized peptide protocols.
How It Works
The CYP450 family metabolizes most peptide-adjacent drugs (SSRIs, beta-blockers, statins). Poor metabolizers hit toxicity at standard doses; ultra-rapid metabolizers need higher doses for effect.
Growth hormone receptor (GHR) exon 3 deletion variant responds more strongly to GH therapy. GLP-1 receptor variants predict weight-loss response to semaglutide and tirzepatide.
MTHFR C677T affects folate metabolism and homocysteine levels. Matters for peptides that interact with methylation pathways — including cognitive-enhancement protocols.
Individual differences in subcutaneous absorption, lymphatic drainage, and local enzyme activity affect peak and duration. Less-studied but clinically real.
What the Data Shows
Key Takeaways
- CYP450 enzyme variants meaningfully affect drug and peptide metabolism
- GH receptor (GHR) and GLP-1 receptor polymorphisms predict therapy response
- MTHFR variants shape folate and methylation biology relevant to cognitive peptides
- 23andMe / Ancestry / Nebula provide actionable pharmacogenomic data
- Pharmacogenomic testing is standard-of-care for several FDA-approved drugs (warfarin, clopidogrel, thiopurines)
- Peptide-specific pharmacogenomic data is sparse — most inference is from adjacent drug classes
- Direct-to-consumer tests have accuracy limits for rare variants
- A genetic variant is a probability shift, not a deterministic response
- Real personalization also requires biomarker tracking, not just genotype
- Physicians who interpret pharmacogenomics well are still uncommon
Frequently Asked Questions
Should I get a pharmacogenomic test before starting peptides?
Not strictly necessary for most research peptides, but useful if you're starting a prescription class like GLP-1s or planning a long-term protocol. 23andMe covers ~80% of actionable variants at consumer price.
What variants matter most for weight-loss peptides?
GLP1R variants predict response magnitude to semaglutide/tirzepatide. FTO variants affect baseline appetite regulation. MC4R variants affect satiety signaling. Standard consumer DNA tests include these.
How does MTHFR affect peptide choices?
C677T variants reduce conversion of folate to methylfolate. Matters most for cognitive peptides (Semax, Selank) where methylation pathways support neurotransmitter synthesis. Folate supplementation is a cheap hedge.
Is there a "peptide genomics" test?
Not as a single product yet. The data you need is in any standard DTC genomics test; interpretation is the challenge. Some concierge clinics offer custom pharmacogenomic panels specifically for peptide protocols.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
This is a framework article covering how genetic variation interacts with peptide response. It is not individualized medical advice. Pharmacogenomic interpretation should involve a qualified clinician.